Bio-Rad Laboratories, Inc.Class A (BIO) Stock Price
BIOStock
$353.70+13.22%52W
Market Cap$9.47B
P/E12.49x
PEG Ratio4.01
Div yield—
Beta1.08
BIO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)11.13%
Price vs S&P 500 (4W)-4.94%
PEG Ratio4.01
VGM Score46.28
P/E Ratio (Annual)12.49x
BIO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.75 | $2.62 | +50.13%(+$0.87) | |
| Q1 2026 | $1.99 | $1.89 | -4.79%(-$0.10) | |
| Q4 2025 | $2.70 | $2.51 | -7.04%(-$0.19) | |
| Q3 2025 | $1.93 | $2.26 | +16.97%(+$0.33) | |
| Q2 2025 | $1.75 | $2.61 | +49.46%(+$0.86) |
BIO Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.50
3.50
3.50
3.50
Industry Peers — Lab Analytical Instruments(25)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
BIOBio-Rad Laboratories, Inc.Class A | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $353.70 |
| AAgilent Technologies Inc. | D | C | A | 6.6x | 5.4% | 53.9% | 22.2% | $172.97 |
| WATWaters Corp | F | C | A | 9.4x | 6.0% | 50.9% | 7.1% | $436.95 |
| ILMNIllumina Inc | D | D | A | 8.8x | 6.0% | 66.4% | 19.5% | $262.54 |
| MTDMettler-Toledo International | D | C | A | 7.9x | 5.5% | 60.3% | 26.6% | $1622.29 |
| RVTYRevvity, Inc. | D | D | A | 5.8x | -5.5% | 55.0% | 12.3% | $152.64 |
| AVTRAvantor, Inc. | C | F | A | 1.7x | 0.5% | 31.8% | -4.7% | $16.42 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $364.15 |
| TXG10x Genomics, Inc. Class A Common Stock | F | D | A | 14.8x | 16.6% | 69.6% | -14.3% | $69.86 |
| BRKRBruker Corporation | D | D | B | 2.4x | 11.6% | 47.7% | -1.5% | $54.80 |
| ALMRAlamar Biosciences, Inc. Common Stock | — | A | B | — | — | — | — | $25.28 |
About Bio-Rad Laboratories, Inc.Class A
Bio-Rad Laboratories manufactures diagnostic systems, quality controls, and life sciences instruments serving clinical labs, research institutions, and biopharmaceutical producers. The company derives 60% of revenue from clinical diagnostics and 40% from life sciences (including dPCR technology leadership), with balanced geographic exposure across Americas (40%), Europe (30%), and Asia (30%). A significant 33% ownership stake in Sartorius provides strategic exposure to the growing single-use biopharmaceutical manufacturing market.